Invention Grant
- Patent Title: Pharmaceutical composition containing indirubin derivative as active ingredient
-
Application No.: US16606089Application Date: 2018-04-10
-
Publication No.: US11459311B2Publication Date: 2022-10-04
- Inventor: Kang-Yell Choi , Gyoonhee Han , Jeong-Ha Hwang , Sehee Choi , Changmok Oh
- Applicant: CK Regeon Inc.
- Applicant Address: KR Seoul
- Assignee: CK Regeon Inc.
- Current Assignee: CK Regeon Inc.
- Current Assignee Address: KR Seoul
- Agency: NSIP Law
- Priority: KR10-2017-0049658 20170418
- International Application: PCT/KR2018/004201 WO 20180410
- International Announcement: WO2018/194309 WO 20181025
- Main IPC: C07D403/04
- IPC: C07D403/04 ; A61P19/00 ; A61P19/10

Abstract:
A composition for promoting longitudinal bone growth, according to the present invention, promotes the proliferation of the chondrocytes and the differentiation of the osteoblasts and has effects of simultaneously increasing longitudinal bone length and thickness (bone density), and thus has an advantage of being widely prescribable to various age groups, thereby being usable as a pharmaceutical composition for promoting the growth of longitudinal bone length and thickness. An indirubin derivative according to the present invention has prevention or treatment effects through oral administration. In addition, unlike conventional therapeutic agents, the pharmaceutical composition for preventing or treating bone diseases of the present invention is a stable compound, which is known to be substantially noncytotoxic to the human body, and is a material of which adverse effects have not been identified and has excellent treatment effects for bone diseases and osteogenesis imperfecta.
Public/Granted literature
- US20200223824A1 PHARMACEUTICAL COMPOSITION CONTAINING INDIRUBIN DERIVATIVE AS ACTIVE INGREDIENT Public/Granted day:2020-07-16
Information query